Works matching AU Nauck, Michael
Results: 163
Metabolic Consequences of Glucagon-Like Peptide-1 Receptor Agonist Shortage: Deterioration of Glycemic Control in Type 2 Diabetes.
- Published in:
- Endocrinology & Metabolism, 2025, v. 40, n. 1, p. 156, doi. 10.3803/EnM.2024.2150
- By:
- Publication type:
- Article
Consensus report: Definition and interpretation of remission in type 2 diabetes.
- Published in:
- Diabetic Medicine, 2022, v. 39, n. 3, p. 1, doi. 10.1111/dme.14669
- By:
- Publication type:
- Article
Comparative evaluation of incretin-based antidiabetic medications and alternative therapies to be added to metformin in the case of monotherapy failure.
- Published in:
- Journal of Diabetes Investigation, 2010, v. 1, n. 1/2, p. 24, doi. 10.1111/j.2040-1124.2010.00004.x
- By:
- Publication type:
- Article
Accurate Measurements of Gastric Emptying and Gastrointestinal Symptoms in the Evaluation of Glucagon-like Peptide-1 Receptor Agonists.
- Published in:
- Annals of Internal Medicine, 2023, v. 176, n. 11, p. 1542, doi. 10.7326/M23-2019
- By:
- Publication type:
- Article
Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Incretins and the development of type 2 diabetes.
- Published in:
- Current Diabetes Reports, 2006, v. 6, n. 3, p. 194, doi. 10.1007/s11892-006-0034-7
- By:
- Publication type:
- Article
A Methodological Framework for Meta-analysis and Clinical Interpretation of Subgroup Data: The Case of Major Adverse Cardiovascular Events With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes.
- Published in:
- Diabetes Care, 2024, v. 47, n. 2, p. 184, doi. 10.2337/dc23-0925
- By:
- Publication type:
- Article
Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Day-to-Day Variations in Fasting Plasma Glucose Do Not Influence Gastric Emptying in Subjects With Type 1 Diabetes.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Reduced COVID-19 Mortality With Sitagliptin Treatment? Weighing the Dissemination of Potentially Lifesaving Findings Against the Assurance of High Scientific Standards.
- Published in:
- Diabetes Care, 2020, v. 43, n. 12, p. 2906, doi. 10.2337/dci20-0062
- By:
- Publication type:
- Article
Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912-1920.
- Published in:
- 2020
- By:
- Publication type:
- Letter
Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Defects in α-Cell Function in Patients With Diabetes Due to Chronic Pancreatitis Compared With Patients With Type 2 Diabetes and Healthy Individuals.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial.
- Published in:
- 2016
- By:
- Publication type:
- journal article
A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Effect of Exogenous Intravenous Administrations of GLP-1 and/or GIP on Circulating Pro-Atrial Natriuretic Peptide in Subjects With Different Stages of Glucose Tolerance.
- Published in:
- Diabetes Care, 2015, v. 38, n. 1, p. e7, doi. 10.2337/dc14-1452
- By:
- Publication type:
- Article
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach.
- Published in:
- Diabetes Care, 2015, v. 38, n. 1, p. 140, doi. 10.2337/dc14-2441
- By:
- Publication type:
- Article
Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes.
- Published in:
- Diabetes Care, 2014, v. 37, n. 10, p. 2763, doi. 10.2337/dc14-0876
- By:
- Publication type:
- Article
Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Beyond Metformin: Safety Considerations in the Decision-Making Process for Selecting a Second Medication for Type 2 Diabetes Management.
- Published in:
- Diabetes Care, 2014, v. 37, n. 9, p. 2647, doi. 10.2337/dc14-1395
- By:
- Publication type:
- Article
Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).
- Published in:
- 2014
- By:
- Publication type:
- journal article
Do GLP-1-Based Therapies Increase Cancer Risk?
- Published in:
- Diabetes Care, 2013, v. 36, n. S2, p. S245, doi. 10.2337/dcS13-2004
- By:
- Publication type:
- Article
A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks.
- Published in:
- 2013
- By:
- Publication type:
- journal article
A Critical Analysis of the Clinical Use of Incretin-Based Therapies.
- Published in:
- Diabetes Care, 2013, v. 36, n. 7, p. 2126, doi. 10.2337/dc12-2504
- By:
- Publication type:
- Article
Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Efficacy and Safety of Switching From the DPP-4 Inhibitor Sitagliptin to the Human GLP-1 Analog Liraglutide After 52 Weeks in Metformin-Treated Patients With Type 2 Diabetes.
- Published in:
- Diabetes Care, 2012, v. 35, n. 10, p. 1986, doi. 10.2337/dc11-2113
- By:
- Publication type:
- Article
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
- Published in:
- 2012
- By:
- Publication type:
- journal article
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach.
- Published in:
- Diabetes Care, 2012, v. 35, n. 6, p. 1364, doi. 10.2337/dc12-0413
- By:
- Publication type:
- Article
Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Chronic Reduction of Fasting Glycemia With Insulin Glargine Improves First- and Second-Phase Insulin Secretion in Patients With Type 2 Diabetes.
- Published in:
- Diabetes Care, 2011, v. 34, n. 9, p. 2048, doi. 10.2337/dc11-0471
- By:
- Publication type:
- Article
Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin.
- Published in:
- Diabetes Care, 2011, v. 34, n. 9, p. 2015, doi. 10.2337/dc11-0606
- By:
- Publication type:
- Article
Genetic determinants predicting efficacy of glucose-lowering drugs?: a long way to go ...
- Published in:
- 2010
- By:
- Publication type:
- Editorial
Genetic Determinants Predicting Efficacy of Glucose-Lowering Drugs?
- Published in:
- 2010
- By:
- Publication type:
- Editorial
Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study.
- Published in:
- 2010
- By:
- Publication type:
- journal article
Further Improvement in Postprandial Glucose Control With Addition of Exenatide or Sitagliptin to Combination Therapy With Insulin Glargine and Metformin.
- Published in:
- Diabetes Care, 2010, v. 33, n. 7, p. 1509, doi. 10.2337/dc09-2191
- By:
- Publication type:
- Article
Incretin-based therapies: viewpoints on the way to consensus.
- Published in:
- 2009
- By:
- Publication type:
- journal article
Incretin-Based Therapies.
- Published in:
- Diabetes Care, 2009, v. 32, p. S223, doi. 10.2337/dc09-S315
- By:
- Publication type:
- Article
Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study.
- Published in:
- 2009
- By:
- Publication type:
- journal article
Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone.
- Published in:
- Diabetes Care, 2009, v. 32, n. 7, p. 1237, doi. 10.2337/dc08-1961
- By:
- Publication type:
- Article
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
- Published in:
- 2009
- By:
- Publication type:
- journal article
Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes.
- Published in:
- Diabetes Care, 2009, v. 32, n. 1, p. 84, doi. 10.2337/dc08-1355
- By:
- Publication type:
- Article
Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study.
- Published in:
- Cardiovascular Diabetology, 2023, v. 22, n. 1, p. 1, doi. 10.1186/s12933-023-01877-6
- By:
- Publication type:
- Article
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.
- Published in:
- Cardiovascular Diabetology, 2022, v. 21, n. 1, p. 1, doi. 10.1186/s12933-022-01604-7
- By:
- Publication type:
- Article
Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes.
- Published in:
- Cardiovascular Diabetology, 2022, v. 21, n. 1, p. 1, doi. 10.1186/s12933-022-01481-0
- By:
- Publication type:
- Article